• No disease-modifying therapy is available for PSP.
• Symptomatic management and supportive care remain the mainstay.
• Multiple clinical trials are ongoing, especially targeting tau pathology, but as of 2025, no therapy has demonstrated efficacy in altering disease progression.
• According to recent reviews, the need for effective PSP therapy is critical, and research is active but has not yet yielded a breakthrough

Decision between coronary artery bypass and stenting is typically determined by extent of blockages as well as patient suitability for open heart surgery. Additionally, other factors such as diabetes and heart strength play a role in deciding what option is better for a certain patient

Treatment for valvular heart disease typically depends on the cause and the type of valvular heart disease. If patient has mostly secondary or functional valvular heart disease, we typically try to address the underlying cause such as weak heart muscle, atrial fibrillation or heart rhythm and treatment of blockages in the heart. First. Heart first. This may be accompanied by or predominantly treated with medications. However, in patience with primary heart valve disease with pathology involving valve tissue in patients with symptoms or causing strain /weakness in heart strength. Typically heart valve repair or replacement is recommended. Choice between open heart surgery versus minimally invasive option treatment depends on patient's age, valve pathology and the risk factors for open surgery.